

**IN THE UNITED STATES DISTRICT COURT
FOR THE NORTHERN DISTRICT OF OKLAHOMA**

(1) THE BOARD OF COUNTY
COMMISSIONERS OF THE COUNTY
OF TULSA,

Plaintiff,

v.

(1) PURDUE PHARMA L.P., et al.,

Defendants.

Case No. CIV-19-205-GKF-FHM
(Removal from: District Court
of Tulsa County, Case No. CJ-2019-1116)

**SPECIAL APPEARANCE AND CORPORATE DISCLOSURE STATEMENT
OF DEFENDANTS TEVA PHARMACEUTICALS USA, INC.,
CEPHALON, INC., ACTAVIS LLC, ACTAVIS PHARMA, INC.
AND WATSON LABORATORIES, INC.**

Pursuant to Federal Rule of Civil Procedure 7.1, Defendants Teva Pharmaceuticals USA, Inc. (“Teva USA”), Cephalon, Inc. (“Cephalon”), Watson Laboratories, Inc. (“Watson”), Actavis LLC (“Actavis LLC”), and Actavis Pharma, Inc. f/k/a Watson Pharma, Inc. (“Actavis Pharma”), appear specially and expressly reserve all available defenses, including but not limited to those related to service of process and personal jurisdiction. Without waving any available defense Defendants make the following disclosures:

1. Defendant Cephalon is directly owned by Cupric Holding Co., Inc., which is directly owned by Teva Pharmaceutical Industries Ltd. (“Teva Ltd.”).

2. Teva Ltd. does not have a parent corporation and no publicly held corporation holds more than 10% or more of its stock.

3. Defendant Teva USA is directly owned by: (i) Orvet UK Unlimited (Majority

Shareholder), which is directly owned by Teva Pharmaceuticals Europe B.V., which is directly owned by Teva Ltd.; and (ii) Teva Pharmaceutical Holdings Coöperatieve U.A. (Minority Shareholder), which is directly owned by IVAX LLC, a direct subsidiary of Teva USA.

4. Defendants Watson, Actavis LLC, and Actavis Pharma are wholly-owned indirect subsidiaries of Teva Ltd.

Respectively Submitted,

/s/ Ashley E. Quinn

ROBERT G. MCCAMPBELL, OBA No. 10390

NICHOLAS V. MERKLEY, OBA No. 20284

KYLE D. EVANS, OBA No. 22135

ASHLEY E. QUINN, OBA No. 33251

GABLEGOTWALS

One Leadership Square, 15th Fl.

211 North Robinson

Oklahoma City, OK 73102-7255

Telephone: (405) 235-3314

RMcCampbell@Gablelaw.com

NMerkley@Gablelaw.com

KEvans@Gablelaw.com

AQuinn@Gablelaw.com

and

Harvey Bartle, IV*

MORGAN, LEWIS & BOCKIUS LLP

502 Carnegie Center

Princeton, New Jersey 08540-6241

T: (609) 919-6685

F: (609) 919-6701

harvey.bartle@morganlewis.com

and

Steven A. Reed*

MORGAN, LEWIS & BOCKIUS LLP

1701 Market Street

Philadelphia, PA 19103

T: 215.963.5000

F: 215.963.5001

steven.reed@morganlewis.com

and

Brian M. Ercole*

MORGAN, LEWIS & BOCKIUS LLP

200 S. Biscayne Blvd., Suite 5300

Miami, FL 33131-2339

T: 305.415.3000

F: 305.415.3001

brian.ercole@morganlewis.com

** denotes national counsel who will seek
pro hac vice admission*

Attorneys for Defendants Teva

Pharmaceuticals, USA, Inc., Cephalon, Inc.,

Watson Laboratories, Inc., Actavis LLC, and

***Actavis Pharma, Inc. F/K/A Watson Pharma,
Inc.***

CERTIFICATE OF SERVICE

I hereby certify that on this 30th day of April, 2019, I electronically transmitted the foregoing document to the Court Clerk using the ECF System for filing. Based on the records currently on file, the Court Clerk will transmit a Notice of Electronic Filing to all ECF registrants.

/s/ Ashley E. Quinn

Ashley E. Quinn